Magnesium Sulfate & Steroids: Newborn Neuroprotection Linked

Recent research suggests the neuroprotective benefits previously attributed to magnesium sulfate administered to mothers during preterm labor may largely stem from the concurrent use of antenatal corticosteroids, rather than the magnesium sulfate itself.

The findings, reported by Medscape Medical News, challenge long-held assumptions about the efficacy of magnesium sulfate in preventing neurological impairment in premature infants. While magnesium sulfate has been a standard of care in periviable deliveries, aiming to reduce the risk of cerebral palsy and other neurological complications, the new data indicates its impact may be secondary to the established benefits of corticosteroids.

Antenatal corticosteroids are administered to pregnant women at risk of preterm birth to accelerate fetal lung maturity and reduce neonatal mortality. Contemporary OB/GYN reported in February 2026 that these corticosteroids continue to demonstrate a significant reduction in neonatal mortality rates among preterm births.

Researchers have been investigating the neuroprotective effects of magnesium sulfate for years. Frontiers published research detailing translational studies and clinical applications of magnesium sulfate for fetal neuroprotection, but the latest analysis suggests the observed benefits may be a result of the combined treatment regimen. The study indicates that the positive outcomes seen in newborns exposed to magnesium sulfate are likely mirrored when corticosteroids are administered, even in the absence of magnesium sulfate.

Further complicating the understanding of magnesium sulfate’s role, a study published in Via Medica Journals examined the effects of antenatal magnesium sulfate on feeding intolerance and necrotizing enterocolitis in preterm infants. While the study explored these specific complications, it did not isolate the independent effect of magnesium sulfate from the concurrent use of other interventions, such as corticosteroids.

A recent report from Medscape also indicated that a study found no benefit for magnesium sulfate in periviable deliveries. This finding further supports the growing body of evidence suggesting the neuroprotective effects are primarily attributable to antenatal corticosteroids.